Healthcare · NIFTY 50
Dr. Reddy's Laboratories Limited
NSEDRREDDY
BSE500124 ISININE089A01031 SeriesEQ Listed on NSE · BSE
₹1,380.00 -6.60 (-0.48%) Updated 13 Nov, 9:19 pm IST
Price, daily close+14.42% in a year
Today
- Open
- ₹1,380.00
- Prev close
- ₹1,386.60
- Day high
- ₹1,404.00
- Day low
- ₹1,375.80
- Volume
- 13.08 L
- Value traded
- ₹181.48 Cr
- Upper circuit
- ₹1,419.90
- Lower circuit
- ₹1,337.30
- 52W high
- ₹1,414.90
- 52W low
- ₹1,101.00
- 1 month
- +16.36%
- 6 months
- +7.27%
52W low52W high
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Market cap₹115,230 Cr
P/E (TTM)41.08
P/B2.97
Book value / share₹464.75
EPS (TTM)₹33.59
ROE7.2%
Dividend yield0.58%
Dividend (12m)₹8.00 / share
Net margin (TTM)8.5%
Operating margin19.9%
Debt / equity0.15
Current ratio1.93
EV / EBITDA24.63
Sales growth (YoY qtr)-1.48%
Profit growth (YoY qtr)-31.35%
Sales CAGR 3Y+10.96%
Profit CAGR 3Y-2.36%
Shares83.50 Cr
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Revenue · QoQ (vs last quarter)
—-1.7%+8.2%+4.4%+4.3%+1.8%+0.5%+3.0%-0.8%-14%+7.3%+7.4%
Revenue · YoY (vs a year ago)
————+16%+20%+11%+9.8%+4.4%-12%-5.5%-1.5%
Net profit · QoQ (vs last quarter)
———-9.8%+13%+13%-11%-5.0%-10%-82%+101%+108%
Net profit · YoY (vs a year ago)
——————+1.8%+7.3%-14%-86%-69%-31%
RevenueNet profitLine = trend
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
EPS (₹) · YoY (vs a year ago)
————-80%-76%-80%+7.4%-14%-86%-69%-31%
EPS (₹)Line = trend
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 | 8,698 |
| Other income | 216 | 198 | 187 | 308 | 150 | 522 | 290 | 324 | 269 | 475 | 355 | 156 |
| Total income | 7,453 | 7,311 | 7,883 | 8,346 | 8,531 | 9,051 | 8,862 | 9,152 | 9,022 | 8,022 | 8,455 | 8,854 |
| Raw material | 1,141 | 1,096 | 1,227 | 1,287 | 1,453 | 1,717 | 2,036 | 1,441 | 1,826 | 1,199 | 1,654 | 1,661 |
| Purchases | 1,208 | 1,176 | 1,380 | 1,283 | 1,051 | 1,128 | 1,216 | 1,746 | 1,542 | 1,658 | 1,974 | 1,538 |
| Employee cost | 1,276 | 1,284 | 1,414 | 1,399 | 1,367 | 1,401 | 1,504 | 1,452 | 1,589 | 1,447 | 1,652 | 1,612 |
| Other expenses | 1,761 | 1,907 | 1,971 | 2,196 | 2,160 | 2,280 | 2,088 | 2,243 | 2,182 | 2,504 | 2,203 | 2,187 |
| Total expenses | 5,627 | 5,710 | 6,007 | 6,434 | 6,661 | 7,051 | 6,958 | 7,414 | 7,481 | 7,827 | 7,902 | 7,619 |
| Operating profit | 2,023 | 1,831 | 2,130 | 2,077 | 2,273 | 1,998 | 2,174 | 2,010 | 1,888 | 383 | 860 | 1,731 |
| OPM % | 28.0% | 25.7% | 27.7% | 25.8% | 27.1% | 23.4% | 25.4% | 22.8% | 21.6% | 5.1% | 10.6% | 19.9% |
| Finance cost | 39.4 | 59.3 | 59.8 | 75.7 | 81.7 | 65.6 | 83.0 | 90.7 | 94.4 | 106 | 126 | 125 |
| Depreciation | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 | 527 |
| Profit before tax | 1,826 | 1,602 | 1,877 | 1,911 | 1,870 | 2,000 | 1,905 | 1,739 | 1,541 | 195 | 553 | 1,235 |
| Tax | 448 | 295 | 490 | 576 | 470 | 419 | 495 | 408 | 354 | -21.6 | 118 | 314 |
| Net profit | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 | 913 |
| Profit to shareholders | 0.0 | 0.0 | — | 1,256 | 1,414 | 1,593 | 1,418 | 1,347 | 1,210 | 221 | 444 | 925 |
| EPS (₹) | 82.81 | 78.53 | 83.48 | 15.05 | 16.94 | 19.10 | 17.02 | 16.17 | 14.52 | 2.65 | 5.33 | 11.09 |
Profit & loss
Results for each year
8 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue · YoY (vs a year ago)
—+13%+8.7%+13%+15%+14%+17%+3.2%
Net profit · YoY (vs a year ago)
—+3.9%-3.7%+12%+107%-100%—-26%
RevenueOperating profitNet profitLine = trend
| ₹ Cr | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 |
| Other income | 338 | 621 | 291 | 484 | 1,056 | 894 | 1,097 | 1,358 |
| Total expenses | 13,494 | 16,308 | 16,503 | 19,039 | 19,714 | 21,719 | 26,083 | 29,679 |
| Employee cost | 3,356 | 3,380 | 3,630 | 3,886 | 4,647 | 5,030 | 5,580 | 5,991 |
| Operating profit | 3,178 | 2,470 | 3,870 | 3,768 | 6,349 | 7,933 | 8,547 | 6,454 |
| OPM % | 20.6% | 14.1% | 20.3% | 17.5% | 25.7% | 28.3% | 26.2% | 19.1% |
| Finance cost | 88.9 | 98.3 | 97.0 | 95.8 | 143 | 171 | 283 | 374 |
| Depreciation | 1,135 | 1,163 | 1,229 | 1,165 | 1,250 | 1,470 | 1,704 | 2,059 |
| Profit before tax | 2,292 | 1,830 | 2,836 | 2,991 | 6,012 | 7,186 | 7,658 | 5,379 |
| Tax | 386 | -140 | 932 | 879 | 1,541 | 1,623 | 1,954 | 1,235 |
| Tax rate % | 16.8% | -7.7% | 32.9% | 29.4% | 25.6% | 22.6% | 25.5% | 23.0% |
| Net profit | 1,950 | 2,026 | 1,952 | 2,183 | 4,507 | 5,578 | 5,725 | 4,158 |
| Profit to shareholders | 1,950 | 2,026 | — | — | — | 0.0 | 5,655 | 4,196 |
| Net margin % | 12.6% | 11.6% | 10.2% | 10.1% | 18.3% | 0.0% | 17.3% | 12.5% |
| EPS (₹) | 117.33 | 121.99 | 117.34 | 131.21 | 270.90 | 334.59 | 67.79 | 50.35 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Mar 23
Mar 24
Mar 25
Mar 26
Sep 26
Shareholders' equity · YoY (vs a year ago)
—+21%+19%+13%—
Shareholders' equityBorrowingsCashLine = trend
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| Shareholders' equity | 23,286 | 28,255 | 33,550 | 37,892 | 38,807 |
| Long-term borrowings | 128 | 380 | 380 | 0.0 | 0.0 |
| Short-term borrowings | 1,219 | 1,272 | 3,805 | 6,294 | 5,826 |
| Total borrowings | 1,347 | 1,652 | 4,185 | 6,294 | 5,826 |
| Current liabilities | 8,572 | 9,588 | 13,034 | 16,747 | 15,430 |
| Fixed assets (PPE) | 5,654 | 6,249 | 7,298 | 10,078 | 10,269 |
| Inventories | 4,867 | 6,355 | 7,109 | 7,653 | 8,118 |
| Trade receivables | 7,249 | 8,030 | 9,042 | 10,123 | 10,140 |
| Cash & equivalents | 578 | 711 | 1,465 | 1,537 | 1,329 |
| Current assets | 20,694 | 24,805 | 25,018 | 30,179 | 29,732 |
| Total assets | 32,285 | 38,864 | 49,427 | 58,123 | 57,631 |
| Debt / equity | 0.06 | 0.06 | 0.12 | 0.17 | 0.15 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
FY22
FY23
FY24
FY25
FY26
Operations · YoY (vs a year ago)
—+109%-23%+2.2%+22%
OperationsInvestingFinancingLine = trend
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 2,811 | 5,887 | 4,543 | 4,643 | 5,674 |
| Cash from investing | -2,639 | -4,137 | -4,028 | -5,102 | -6,549 |
| Cash from financing | -242 | -2,686 | -376 | 1,186 | 829 |
| Spent on fixed assets | -1,466 | -1,132 | -1,640 | -2,750 | -2,331 |
| Free cash flow | 1,345 | 4,755 | 2,903 | 1,892 | 3,343 |
| Net cash flow | -70.1 | -936 | 139 | 726 | -46.6 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Promoter & groupPublic
Latest (30 Sep 2026)
26.6%promoter
- Promoter & group
- 26.63%
- Public (FIIs, mutual funds, retail…)
- 73.17%
- Employee trusts
- 0.19%
- Promoter change, last quarter
- -0.01 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Dividend - Rs 8 Per Share
- Dividend - Rs 8 Per Share
- Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share
- Annual General Meeting/Dividend - Rs 40 Per Share
- Annual General Meeting/Dividend - Rs 40 Per Share
- Annual General Meeting/Dividend - Rs 30 Per Share
- Annual General Meeting/Dividend - Rs 25 Per Share
- Annual General Meeting/Dividend - Rs 25 Per Share
Board meetings
- Dr. Reddy's Laboratories Limited has informed the Exchange about Board Meeting to be held on 23-Oct-2026 to inter-alia consider and approve the Unaud…
- the financial results for the period ended September 30, 2026
- Dr. Reddy's Laboratories Limited has informed the Exchange about Board Meeting to be held on 22-Jul-2026 to inter-alia consider and approve the Unaud…
- the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ending on June 30, 2026
- To recommend final dividend, if any, for the Financial year 2025-26
Filings with NSE
- Copy of Newspaper Publication
- Analysts/Institutional Investor Meet/Con. Call Updates
- Press Release
- General Updates
- News Verification
- Analysts/Institutional Investor Meet/Con. Call Updates
- General Updates
Latest news
Dr Reddy's Labs shares tank 9% to 52-week low after Q1 show. Time to sell?Business Standard · 23 Jul, 12:30 pmDr Reddy’s Laboratories: Two major announcements to impact stock in near termBusiness Today · 9 Oct, 12:30 pmDr Reddy's Laboratories Shares Rise 2.24%Moneycontrol.com · 11 Aug, 12:30 pmDr. Reddy's Laboratories shares fall 7% as most analysts remain bearish after Q1 earnings missCNBC TV18 · 23 Jul, 12:30 pmWhy Dr Reddys Laboratories Share Price is RisingEquitymaster · 22 Jan, 1:30 pmDr Reddy's Laboratories shares volatile after an 86% YoY decline in Q4 profit. Should you buy?Livemint · 13 May, 12:30 pmDr. Reddy's Laboratories Share Price Fall Streak: 2.28%Univest · 1 Oct, 12:30 pmDr Reddy's Laboratories shares fall 4.02 percent in today's sessionMoneycontrol.com · 23 Jul, 12:30 pmAbout
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Dr. Reddy's Laboratories Limited
- NSE symbol
- DRREDDY
- BSE scrip code
- 500124
- ISIN
- INE089A01031
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 30 May 2003
- Face value
- ₹1 per share
- Market lot
- 1 share
- Shares issued
- 83.50 crore
- Index
- NIFTY 50, NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Major
- Managing director / CEO
- Erez Israeli
- Chair
- K. Satish Reddy
- Headquarters
- Hyderabad, Telangana, India
- Registered address
- 8-2-337, Road No. 3, Banjara Hills, Hyderabad – 500 034, Telangana, India
- Founded
- 1984
- Employees
- 27,527
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- drreddys.com
Peers
Other Healthcare stocks
-
DIVISLABDivi's Laboratories
₹11,442.00
-0.37%
-
LAURUSLABSLaurus Labs
₹2,424.00
+1.00%
-
APOLLOHOSPApollo Hospitals Enterprise
₹8,526.00
+0.13%
-
SUNPHARMASun Pharmaceutical Industries
₹1,880.00
-0.27%
-
SAILIFESai Life Sciences
₹1,928.80
+1.24%
-
NATCOPHARMNATCO Pharma
₹810.45
+0.20%
-
ACUTAASAcutaas Chemicals
₹4,055.00
+1.47%
-
AUROPHARMAAurobindo Pharma
₹1,823.20
+0.89%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.